It will be nigh impossible to orchestrate a complete lockdown in a country like Indonesia and the situation could be made worse with the upcoming Lebaran celebrations,Īs to the economic impact, it is difficult to make any meaningful estimates but we can probably assume very slow if any growth this year, with domestic consumption subdued at best, not helped by the collapse in commodity prices. He also just announced a ban on foreign arrivals which will stem imported cases. President Jokowi is now taking firm action and has started to put through firm measures to contain the virus declaring a state of emergency. This will not be an easy task given the sheer size of the Indonesian population, as well as its densely populated cities. CrossASEAN Strategy – Indonesia in a COVID-19 WorldĪfter a period of living in misguided denial on COVID-19, Indonesia has finally admitted its fallibility and grasped the nettle on trying to bring the spread of COVID19 under control. While a large degree of uncertainty lingers on how the virus outbreak will play out, we remain optimistic about TCEL’s long-term prospects given its key foothold in China’s lower-tier cities and digital asset-light model allowing it to quickly adapt its cost structure to the new climate.ģ. We believe this is a boon to OTAs like TCEL that primarily operate domestically – allowing them to rebound faster compared to global peers like TCOM that rely on international business as a key growth driver. Early Signs of Chinese Travel Recovery Domestic OTAs like TCEL Can Rebound Faster than TCOMĬhinese domestic travel is showing early signs of recovery as business travelers begin to go back to work, and people’s fears about the virus subside. Jinxin Fertility (锦欣生殖) Placement – A Good Point of EntryĢ.Jinxin Fertility (锦欣生殖) Post-IPO Trading: Fairly Valued.Jinxin Fertility (锦欣生殖) IPO – Worth a Look Given the Sector, Existing Shareholders and Cornerstone. Jinxin Fertility (锦欣生殖) Pre-IPO: Strong Foothold in Sichuan but Weak Sentiment for Sector.Our previous coverage on Jinxin Fertility The current weak share performance offers great opportunities to accumulate the stock. In 2019, the company has achieved a strong growth and looking ahead into 2020, despite being plagued by the covid-19 outbreak, we believe the company’s growth story is intact and visible. We believe the stock is a candidate for bottom fishing during market turmoil. While we don’t intend to cover the full result analysis, we would like to highlight key takeaways from the results and our research on the company. Jinxin Fertility has recently reported its results on March 31st. Bottom Fishing Idea – Jinxin Fertility: IVF Story Intact Kangji Medical (康基医疗) Pre-IPO: Track Record of Growth but Products Too Concentratedġ.I-Mab Biopharma (IMAB.US): Emerging I/O Winner Brighter Outlook with Accelerating R&D Progress.CrossASEAN Strategy – Indonesia in a COVID-19 World.Early Signs of Chinese Travel Recovery Domestic OTAs like TCEL Can Rebound Faster than TCOM.Bottom Fishing Idea – Jinxin Fertility: IVF Story Intact.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |